Development and validation of an egg-based potency assay for a trivalent live attenuated influenza vaccine

Biologicals

Volumn 40, Issue 2, 2012, Pages 146-150

  Yeolekar, Leena R ^a   Dhere, Rajeev M ^a  

^a Serum Institute of India Limited   (India)

Author keywords

Egg infectious dose; Live attenuated influenza vaccine; Potency

Indexed keywords

INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; INFLUENZA A; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS STRAIN; VIRUS TITRATION;

ANIMALS; ANTIBODIES, HETEROPHILE; ANTIBODIES, VIRAL; CHICK EMBRYO; IMMUNOASSAY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; NEUTRALIZATION TESTS; SHEEP; VACCINES, ATTENUATED;

EID: 84858076155     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2011.10.002     Document Type: Article

References (11)

1. WHO Global Alert and Response (GAR) recommendations for influenza vaccine http://www.who.int/csr/disease/influenza/vaccinerecommendations/en/index.html.
2. Naǐkhin A.N., Rekstin A.R., Barantseva I.B., Donina S.A., Desheva Iu A., Grigor'eva E.P., et al. Immune response to live influenza vaccine. Vestn Ross Akad Med Nauk 2002, 12:24-28. [Article in Russian].
3. WHO recommendations to assure the quality, safety, and efficacy of influenza vaccines (human, live attenuated) for intranasal administration http://www.who.int/biologicals/areas/vaccines/influenza/Influenza-vaccines-final-14MAY-2010.pdf.
4. Recommendation for the production and control of poliomyelitis vaccine (oral) 2002, vol. 31. WHO Technical report series No. 904 Annex 1.
5. Requirement for measles, mumps and rubella vaccines and combined vaccine (live) 1994, vol. 100. WHO Technical Report Series No 840 Annex 3.
6. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042.
7. Recommended composition of influenza virus vaccines for use in the 2011 southern hemisphere influenza season http://www.who.int/csr/disease/influenza/recommendations2011south/en/index.html.
8. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season http://www.who.int/csr/disease/influenza/recommendations-2011-12north/en/index.html.
9. Reed L.J., Muench H. A simple method of estimating fifty percent endpoint. Amer J Hyg 1938, 375:493.
10. EMEA-European Medicines Agency ICH Topic Q2(R1). Validation of analytical procedures: text and methodology June 1995, CPMP/ICH/381/95. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002662.pdf.
11. Kendal A.P., Pereira M.S., Skehel J.J. Concepts and procedures for laboratory based influenza surveillance 1982, B17-B24. Centre for Disease Control and Prevention, Atlanta, GA, USA.